| Download a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
The Chilean pharmaceutical market is the sixth largest market in the region,
after Mexico, Brazil, Argentina, Venezuela and Colombia. This report is ideal
for executives wanting to understand the key drivers in the pharmaceutical
market and have access to a wealth of statistical data, including five-year
market projections. Included with the report are 3 free quarterly updated
outlook reports, enabling you to keep up to date with market developments for
a year.
Includes 3 quarterly updated outlook reports!
The pharmacy sector was valued at US$839.0 million at manufacturers' prices in
2006. LabChile continues to be the leading producer. Other leading producers
include Recalcine, Saval and Andromaco. LabChile was acquired by IVAX in 2001
but is currently owned by Teva, following Teva's acquisition of IVAX. In March
2005, Andromaco acquired Silesia, further consolidating the sector. The
largest producers meet GMP standards but smaller producers have not fully
complied. Bioequivalence standards are not compulsory yet although tests are
being performed on selected active ingredients.
Pharmacy prices are still among the lowest in the region. The pharmacy chains
Cruz Verde, Farmacias Ahumada and SalcoBrand control around 90% of the
pharmacy sector. As the distribution channel is so consolidated, these
pharmacy chains are engaged in aggressive price wars. They also practice
own-label production, vertical distribution and product & market
diversification. For instance, Farmacias Ahumada operates in Mexico and Peru,
although market entry in Brazil has been unsuccessful. In the Chilean hospital
sector, CENABAST centralises expenditure on pharmaceuticals.
In January 2004, an Ethics Code (Codigo de Etica) was enforced to solve
discrepancies between national and foreign producers, in terms of regulation,
consumer rights, respect to the industry, competition and advertising. Under
the Chilean Industrial Society (SOFOFA - Sociedad de Fomento Fabril), an
Ethics Commission was also created to act as intermediary. The Ethics Code is
based on SOFOFA's ethical regulations and regulations issued by the Chilean
Association of Advertising Agencies (ACHAP - Asociacion Chilena de Agencias
de Publicidad).
Between 1999 and 2004, a new patent law was under debate to bring Chilean
patent law in line with international standards, including TRIPS compliance.
The law should have been enforced in January 2000 according to the WTO-imposed
deadline, but was fiercely resisted by domestic producers. Finally, the
Chamber of Deputies and the Senate approved the modifications to Law No.
19,039 in November 2004. The new Law No. 19,996 was published in the official
bulletin (DO - Diario Oficial) in March 2005. Nevetheless, the United States
Trade Representative (USTRP) placed Chile on the 2006 Watch List.
TABLE OF CONTENTS
CHILE: BACKGROUND DATA
- GEOGRAPHY
- POLITICAL OVERVIEW
- ECONOMIC OVERVIEW
- GDP, 1990-2012
- POPULATION
- Projected Population, 2000-2012
- Population by Region, 2002 Census
- Projected Population by Age, 1975-2025
- Projected Population by Age, 1975-2025 (%)
- DEMOGRAPHIC INDICATORS
- Demographic Indicators, 1997-2004
- MORTALITY
- Selected Causes of Death, 1999-2004
- Selected Causes of Death by Sex, 2004
- Selected Specific Causes of Death, 2004
- Infant Mortality
- Infant Deaths by Cause, 2003
- MORBIDITY
- Reported and Cumulative Cases of Selected Infectious Diseases, 2004-2005
- HIV/AIDS
- Reported AIDS Cases, 1984-2003
- Estimated AIDS & HIV Cases, 2003
CHARTS
- Map of Chile
- Population by Age, 1975-2025 (%)
- Selected Causes of Death, 2004
CHILE: HEALTHCARE SYSTEM
- ORGANISATION & ADMINISTRATION
- Health Beneficiaries, 1990-2006
- SNSS / FONASA
- Isapres
- Isapres' Beneficiaries, 1990-2006
- Beneficiaries by Isapre Type, 2006
- The Reform
- SWOT Analysis of the Chilean Health System, 2005
- Major Structural Implementations, 2000-2010
- The Five-Law Reform Bill, 2004
- AUGE Pilot Programme Patients, August 2002-November 2004
- Isapres' Solvency Bill, 2004
- HEALTH EXPENDITURE
- Health Expenditure, 1998-2003 (US$ Billion)
- Health Expenditure, 1998-2003 (%)
- Public Health Expenditure
- Public Health Expenditure, 1990-2005
- Public Health Expenditure by Source of Income, 1990-2005 (%)
- Isapres' Health Expenditure
- Isapres' Operational Revenues, 1999-2005
- Isapres' Balance Sheet, 2004-2005
- HOSPITAL SERVICES
- Hospital Resources
- Hospitals by Provider, 1998-2003
- Hospital Beds by Provider, 1998-2003
- Hospital Beds by Region & Provider, 2003
- Hospital Activity
- Hospital Discharges, 1997-2004
- Hospital Activity by Provision & Insurance Affiliation, 2000 (%)
- Hospital Discharges by Cause, 2001
- SNSS Hospital Indicators, 1994-2004
- SNSS Hospital Activity, 1997-2001
- Free Election System Activity, 2002-2004
- Free Election System Activity by Type of Treatment, 2002-2004
- Isapres Activity, 1990-2002 (000s)
- Isapres Activity by Type of Treatment, 2001-2002 (000s)
- Isapres' Discharges by Cause, 2001 (000s)
- Hospital Investments
- Hospital Investments, 2003-2007 (Million Pesos)
- Hospital Investment Projects, 2003-2007
- Projects for PPA Funding, 2004 (Million Pesos)
- Areas for PPA Funding, 2004
- AMBULATORY CARE
- SNSS Outpatient Facilities, 1998-2003
- Medical Consultations by Programme, 1999-2003
- Medical Treatment by Type, Place of Treatment & Health Insurance, 2000 (%)
- MEDICAL PERSONNEL
- Doctors by Specialty, 1999-2004
- Doctors by Age Group & Sex, 2004
- Doctors by Regional Council & Sex, 2004
- SNSS Personnel, 1998-2003
CHARTS
- Reformed Functional Organisation
- Isapres' Beneficiaries, 1990-2006
- Beneficiaries by Isapre Type, 2006 (%)
- Private Health Expenditure by Source of Funding, 2000-2003 (%)
- Public Health Expenditure by Source of Income, 1990-2005 (%)
- Isapres' Operational Revenues, 1999-2005
- Isapres' Balance Sheet, 2005 (%)
- Hospitals by Provider, 1998-2003
- Hospital Beds by Provider, 1998-2003
- Hospital Beds by Region, 2003 (Rate per 1,000 Population)
- Doctors, 1995-2004
- Selected SNSS Medical Personnel, 1998-2003
CHILE: ACCESSING THE PHARMACEUTICAL MARKET
- INTRODUCTION
- REGULATORY ENVIRONMENT
- Registration
- Number of Product Registrations, 1999-2002
- Quality Standards
- Stock Control
- Legal Proceedings
- Advertising
- Patent Protection & Intellectual Property Rights
- Pharmaceutical Patent Applications
- Cumulative Pharmaceutical Applications, September 1991- April 2002
- Pricing
- Reimbursement
- DISTRIBUTION CHANNELS
- Pharmacy Own-Labelled Production
- Retail Pharmacy Chains
- Cruz Verde
- Farmacias Ahumada
- Farmacias SalcoBrand
- FarmaLider
- CENABAST
- TRADE FAIRS
- EXPOSALUD 2007
- DOMESTIC PRODUCTION
- Trade Associations
- ASILFA
- ASILFA's Members, 2007
- CAMEVED
- CANALAB
- CANALAB's Members, 2007
- CIF
- CIF's Members, 2007
- Domestic Producers
- Andromaco
- Financial Indicators
- Andromaco's Sales, 2000-2005 (Billion Pesos)
- Product Portfolio
- Manufacturing Capabilities
- Exports
- International Divisions
- Bago
- Financial Indicators
- Product Portfolio
- Manufacturing Capabilities
- Exports
- Bestpharma
- Product Portfolio
- Biosano
- Financial Indicators
- Product Portfolio
- Biosano's Product Portfolio, 2007
- Manufacturing Capabilities
- LabChile
- Financial Indicators
- Product Portfolio
- Manufacturing Capabilities
- Exports
- Distribution
- Labomed
- Pharmaceutical Producers Represented by Labomed, 2007
- Maver
- Mintlab
- Recalcine
- Financial Indicators
- Product Portfolio
- Manufacturing Capabilities
- Sanderson
- Financial Indicators
- Product Portfolio
- Manufacturing Capabilities
- Exports
- Saval
- Financial Indicators
- Product Portfolio
- Manufacturing Capabilities
- Exports
- Research & Development
- DIRECTORY
- Government Organisations
- Trade Associations
CHARTS
- Drug Pricing by Product Type, 2002-2005 (US$)
- Pharmacy Sector by Distribution Channels, 2006 (%)
- FASA's Sales, 2000-2005
- Andromaco's Sales, 2000-2005
- Saval's Sales, 2003-2006
|
